Neuroimaging Features of Neurodegeneration with Brain Iron Accumulation

References

1. 1.↵
   1. McNeill A,
   2. Birchall D,
   3. Hayflick SJ,
   4. et al

   . T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology 2008; 29;70: 1614– 19
2. 2.↵
   1. Yilmaz A,
   2. Budak H,
   3. Longo R

   . Paramagnetic contribution of serum iron to the spin-lattice relaxation rate (1//'1) determined by MRI. Appl Magn Reson 1998; 14: 51– 58

   CrossRef
3. 3.↵
   1. Burgetova A,
   2. Seidl Z,
   3. Krasensky J,
   4. et al

   . Multiple sclerosis and the accumulation of iron in the basal ganglia: quantitative assessment of brain iron using MRI t(2) relaxometry. Eur Neurol 2010; 63: 136– 43

   CrossRefPubMed
4. 4.↵
   1. Miszkiel KA,
   2. Paley MN,
   3. Wilkinson ID,
   4. et al

   . The measurement of R2, R2* and R2′ in HIV-infected patients using the prime sequence as a measure of brain iron deposition. Magn Reson Imaging 1997; 15: 1113– 19

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Waldvogel D,
   2. van Gelderen P,
   3. Hallett M

   . Increased iron in the dentate nucleus of patients with Friedrich's ataxia. Ann Neurol 1999; 46: 123– 25

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Brar S,
   2. Henderson D,
   3. Schenck J,
   4. et al

   . Iron accumulation in the substantia nigra of patients with Alzheimer disease and parkinsonism. Arch Neurol 2009; 66: 371– 74

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Gerlach M,
   2. Ben-Shachar D,
   3. Riederer P,
   4. et al

   . Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 1994; 63: 793– 807

   PubMedWeb of Science
8. 8.↵
   1. Kobari M,
   2. Nogawa S,
   3. Sugimoto Y,
   4. et al

   . Familial idiopathic brain calcification with autosomal dominant inheritance. Neurology 1997; 48: 645– 49

   Abstract/FREE Full Text
9. 9.↵
   1. Storey P,
   2. Thompson AA,
   3. Carqueville CL,
   4. et al

   . R2* imaging of transfusional iron burden at 3T and comparison with 1.5T. J Magn Reson Imaging 2007; 25: 540– 47

   CrossRefPubMed
10. 10.↵
    1. Hallgren B,
    2. Sourander P

    . The Effect of age on the non-haemin iron in the human brain. J Neurochem 1958; 3: 41– 51

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Aquino D,
    2. Bizzi A,
    3. Grisoli M,
    4. et al

    . Age-related iron deposition in the basal ganglia: quantitative analysis in healthy subjects. Radiology 2009; 252: 165– 72

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Boddaert N,
    2. Le Quan Sang KH,
    3. Rötig A,
    4. et al

    . Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007; 110: 401– 08

    Abstract/FREE Full Text
13. 13.↵
    1. Hayflick SJ,
    2. Penzien JM,
    3. Michl W,
    4. et al

    . Cranial MRI changes may precede symptoms in Hallervorden-Spatz syndrome. Pediatr Neurol 2001; 25: 166– 69

    CrossRefPubMed
14. 14.↵
    1. Gregory A,
    2. Westaway SK,
    3. Holm IE,
    4. et al

    . Neurodegeneration associated with genetic defects in phospholipase A(2). Neurology 2008; 71: 1402– 09

    Abstract/FREE Full Text
15. 15.↵
    1. Forni GL,
    2. Balocco M,
    3. Cremonesi L,
    4. et al

    . Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation. Mov Disord 2008; 23: 904– 07

    CrossRefPubMed
16. 16.↵
    1. Zhou B,
    2. Westaway SK,
    3. Levinson B,
    4. et al

    . A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001; 28: 345– 49

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Freeman K,
    2. Gregory A,
    3. Turner A,
    4. et al

    . Intellectual and adaptive behaviour functioning in pantothenate kinase-associated neurodegeneration. J Intellect Disabil Res 2007; 51 (pt 6): 417– 26

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Kumar N,
    2. Boes CJ,
    3. Babovic-Vuksanovic D,
    4. et al

    . The “eye-of-the-tiger” sign is not pathognomonic of the PANK2 mutation. Arch Neurol 2006; 63: 292– 93

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Kruer MC,
    2. Hiken M,
    3. Gregory A,
    4. et al

    . Novel histopathologic findings in molecularly-confirmed pantothenate kinase-associated neurodegeneration. Brain 2011; 134 (pt 4): 947– 58

    Abstract/FREE Full Text
20. 20.↵
    1. Hayflick SJ,
    2. Hartman M,
    3. Coryell J,
    4. et al

    . Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. AJNR Am J Neuroradiol 2006; 27: 1230– 33

    Abstract/FREE Full Text
21. 21.↵
    1. Baumeister FA,
    2. Auer DP,
    3. Hörtnagel K,
    4. et al

    . The eye-of-the-tiger sign is not a reliable disease marker for Hallervorden-Spatz syndrome. Neuropediatrics 2005; 36: 221– 22

    CrossRefPubMed
22. 22.↵
    1. Strecker K,
    2. Hesse S,
    3. Wegner F,
    4. et al

    . Eye of the tiger sign in multiple system atrophy. Eur J Neurol 2007; 14: e1– 2

    CrossRefPubMed
23. 23.↵
    1. Molinuevo JL,
    2. Muñoz E,
    3. Valldeoriola F,
    4. et al

    . The eye of the tiger sign in cortical-basal ganglionic degeneration. Mov Disord 1999; 14: 169– 71

    CrossRefPubMed
24. 24.↵
    1. Morgan NV,
    2. Westaway SK,
    3. Morton JE,
    4. et al

    . PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet 2006; 38: 752– 54

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Wild EJ,
    2. Mudanohwo EE,
    3. Sweeney MG,
    4. et al

    . Huntington's disease phenocopies are clinically and genetically heterogeneous. Mov Disord 2008; 23: 716– 20

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Chinnery PF,
    2. Crompton DE,
    3. Birchall D,
    4. et al

    . Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 2007; 130 (pt 1): 110– 19. Epub 2006 Dec 2

    Abstract/FREE Full Text
27. 27.↵
    1. di Patti MC,
    2. Maio N,
    3. Rizzo G,
    4. et al

    . Dominant mutants of ceruloplasmin impair the copper loading machinery in aceruloplasminemia. J Biol Chem 2009; 284: 4545– 54. Epub 2008 Dec 18

    Abstract/FREE Full Text
28. 28.↵
    1. Merle U,
    2. Tuma S,
    3. Herrmann T,
    4. et al

    . Evidence for a critical role of ceruloplasmin oxidase activity in iron metabolism of Wilson disease gene knockout mice. J Gastroenterol Hepatol 2010; 25: 1144– 50

    PubMed
29. 29.↵
    1. Kruer MC,
    2. Paisán-Ruiz C,
    3. Boddaert N,
    4. et al

    . Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA). Ann Neurol 2010; 68: 611– 18.

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Schneider SA,
    2. Paisan-Ruiz C,
    3. Quinn NP,
    4. et al

    . ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord 2010; 25: 979– 84

    CrossRefPubMed
31. 31.↵
    1. Behrens MI,
    2. Brüggemann N,
    3. Chana P,
    4. et al

    . Clinical spectrum of Kufor-Rakeb syndrome in the Chilean kindred with ATP13A2 mutations. Mov Disord 2010; 25: 1929– 37

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Alazami AM,
    2. Al-Saif A,
    3. Al-Semari A,
    4. et al

    . Mutations in C2orf37, encoding a nucleolar protein, cause hypogonadism, alopecia, diabetes mellitus, mental retardation, and extrapyramidal syndrome. Am J Hum Genet 2008; 83: 684– 91

    CrossRefPubMed
33. 33.↵
    1. Kuo YM,
    2. Hayflick SJ,
    3. Gitschier J

    . Deprivation of pantothenic acid elicits a movement disorder and azoospermia in a mouse model of pantothenate kinase-associated neurodegeneration. J Inherit Metab Dis 2007; 30: 310– 17

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Kruer MC,
    2. Gregory A,
    3. Hogarth P,
    4. et al

    . Childhood static encephalopathy and cerebral palsy followed by abrupt-onset progressive neurodegeneration in adulthood: a novel neurodegeneration with brain iron accumulation (NBIA) phenotype. Poster presentations, American Academy of Cerebral Palsy and Developmental Medicine 63rd Annual Meeting, Scottsdale, AZ, September 2009.
35. 35.↵
    1. Hayflick SJ

    . Dystonia-parkinsonism disease gene discovery: expect surprises. Ann Neurol 2009; 65: 2– 3

    CrossRefPubMed
36. 36.↵
    1. Paisan-Ruiz C,
    2. Bhatia KP,
    3. Li A,
    4. et al

    . Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol 2009; 65: 19– 23

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Kurian MA,
    2. Morgan NV,
    3. MacPherson L,
    4. et al

    . Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). Neurology 2008; 70: 1623– 29

    Abstract/FREE Full Text
38. 38.↵
    1. Paisán-Ruiz C,
    2. Li A,
    3. Schneider SA,
    4. et al

    . Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiol Aging 2010; 33: 814– 23

    PubMed
39. 39.↵
    1. Galvin JE,
    2. Giasson B,
    3. Hurtig HI,
    4. et al

    . Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. Am J Pathol 2000; 157: 361– 68

    PubMedWeb of Science
40. 40.↵
    1. Wakabayashi K,
    2. Fukushima T,
    3. Koide R,
    4. et al

    . Juvenile-onset generalized neuroaxonal dystrophy (Hallervorden-Spatz disease) with diffuse neurofibrillary and Lewy body pathology. Acta Neuropathol 2000; 99: 331– 36

    CrossRefPubMed